Misplaced Pages

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

References

1. Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
2. "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
3. WHO Drug Information

External links

• Official website

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs